Latest Stock Market News

Paytm founder and chief executive Vijay Shekhar Sharma told employees in a town hall that they need not read too much into the criticism of its business model after its shares crashed on listing last week, and that the company in its history has never had anything easy up front.

Zydus Cadila said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in the American market.

The number of its monthly transacting users (MTU) grew more than 35% in October this year to 63 million, compared with 47 million the same month last year. GMV per MTU increased to $177 from $104.

"You should be able to avoid the behavioural biases and emotions that often get in the way of optimal investment decision making. A good mid-path that can combine the benefits of both the traditional active approach and the passive approach. Something that we like to call the Passive+ approach. This approach combines the strong suits of both the traditional active management approach and the passive investing approach to create a rule based investment portfolio."

Kesoram Industries board on Saturday approved to raise fund up to Rs. 2,500 crore to lower the cost of borrowing to replace high-cost NCDs and OCDs. The company said that it can raise the fresh funds by way of equity, bond, foreign currency floats, or other instruments.

"Unless the Nifty moves back above 17850, it will continue to trade weak with a corrective undertone."

“While Paytm was expected to be a blockbuster listing, it did not happen that way.”

Paytm target downgrade and a sudden shift in momentum puts the spotlight on the mean – or, more precisely, reversion to the mean.

Following the relentless selling pressure in the past three trading sessions, the index has now reached oversold territory on shorter time frame charts, suggesting a possible pullback short covering rally to 17,900-17,980 levels.

The company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement. Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer.